Uncategorized

Regeneron ends eye disease trial for anti-CD3 antibody following safety review

Published

on

Regeneron has hit the brakes on the phase 1/2a trial for an experimental eye inflammation treatment, following an adverse event that tilted the drug’s risk/benefit profile in the wrong direction.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version